Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of filgotinib in rheumatoid arthritis
2012-003655-11Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgotinib in rheumatoid arthritis (RA), sponsored by Galapagos NV. Primary endpoint: Long-term safety and tolerability of filgotinib. Started Oct 2013; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2012-003655-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003655-11.